COMMUNIQUÉS West-GlobeNewswire

Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
14/05/2024
Apellis received $375 million in funding at close, with ability to access an additional $100 million Majority of initial proceeds used to buy out existing SFJ Pharmaceuticals development liability Significantly improves [...]
Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
14/05/2024
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy [...]
Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
14/05/2024
– Gained alignment with U.S. Food and Drug Administration (FDA) on brilaroxazine clinical trials for New Drug Application (NDA) submission in schizophrenia – – Registrational RECOVER-2 trial expected to initiate Q2 2024 [...]
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
14/05/2024
Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data are anticipated in Takeda's H1 2024 fiscal year A Phase 1, double-blind, multiple [...]
Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting
14/05/2024
PDAT clinical outcomes for infectious keratitis from Brazil and Mexico KNOXVILLE, TN, May 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that [...]
Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules
14/05/2024
The Company has also completed the GMP validation work allowing for the release of both MDMA dosage formats VANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) ( [...]
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
14/05/2024
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC [...]
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
14/05/2024
Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in [...]
Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter
14/05/2024
Best Quarterly Results in Company’s History from a Financial Perspective. EBITDA Improvements Driven by Record Revenues, Record Margins and Operational Efficiencies. Marketing Authorization of Trunerox™ in Colombia by [...]
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
14/05/2024
Cash runway extended into July 2025 from previously April 2025 Capital raise strengthens Medigene’s financial position Lead program, MDG1015, on track for IND filing in 3Q 2024 and CTA filing in 4Q 2024 Use of proceeds [...]
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
14/05/2024
~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~ ~ Executed Exclusive Licensing Agreement with Norgine to [...]
Rejuvine Life Sciences Launches Crowdfunding Campaign to Revolutionize Diabetes Management with Science-Backed, Natural Solutions
14/05/2024
We believe everyone deserves access to safe and effective healthcare solutions. MIDDLETOWN, Del., May 14, 2024 (GLOBE NEWSWIRE) -- via IBN -- Rejuvine Life Sciences , dedicated to developing natural healthcare solutions [...]
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
14/05/2024
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an enzymatic route to [...]
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
14/05/2024
LA JOLLA, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), [...]
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector
14/05/2024
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector Paris - France - May 14, 2024 - The Alliance [...]
L'Alliance Promotion Microbiote devient l’European Microbiome Innovation for Health : une étape majeure pour structurer la filière d’excellence européenne du microbiote
14/05/2024
L'Alliance Promotion Microbiote devient l’European Microbiome Innovation for Health : une étape majeure pour structurer la filière d’excellence européenne du microbiote Paris - France – 14 mai 2024 – L’Alliance [...]
Periodemeddelelse Første Kvartal 2024
14/05/2024
Selskabet har opnået følgende resultat for første kvartal 2024: EBIT: negativt DKK 0.9 mio. De strategiske partnerskaber har bidraget med en indtægt på DKK 0.6 mio. Egenkapital ultimo marts 2024: DKK 13.4 mio. Business [...]
Coloplast expands its Luja™ portfolio with next generation catheter for women
14/05/2024
The female intermittent catheter enables complete bladder emptying in one free flow 1 , aiming to reduce the risk of urinary tract infections 2 . Following the successful launch of Luja with Micro-hole Zone Technology, [...]
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Advisor to its Board and Chair of its R&D Committee
14/05/2024
Dr. Gallagher, current President of R&D at Syndax Pharmaceuticals and former Chief Medical Officer and Head of Development at AbbVie, brings significant experience of end-to-end development that has resulted in the [...]

Pages